ArticleAntimicrobial agents and chemotherapy2017
Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Layering vaccination with antibiotic therapy results in protection and clearance ofInfection and immunity · 2024Article
- Article
- Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis.Microbiology spectrum · 2023Article
- Efficacy of ceftazidime in a murine model following a lethal aerosol exposure to Burkholderia pseudomallei.Scientific reports · 2023Article
- The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with AerosolizedAntibiotics (Basel, Switzerland) · 2023Article
- A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.Molecules (Basel, Switzerland) · 2023Review
- An Investigation into the Re-Emergence of Disease Following Cessation of Antibiotic Treatment in Balb/c Mice Infected with InhalationalAntibiotics (Basel, Switzerland) · 2022Article
- Investigation of a combination therapy approach for the treatment of melioidosis.Frontiers in microbiology · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- Efficacy of finafloxacin in a murine model of inhalational glanders.Frontiers in microbiology · 2022Article
- Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.Antibiotics (Basel, Switzerland) · 2021Review
- Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei.Antimicrobial agents and chemotherapy · 2021Article
- Finafloxacin Is an Effective Treatment for Inhalational Tularemia and Plague in Mouse Models of Infection.Antimicrobial agents and chemotherapy · 2021Article
- A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever.Frontiers in microbiology · 2021Article
- Human Melioidosis.Clinical microbiology reviews · 2020Review
- Emerging role of biologics for the treatment of melioidosis and glanders.Expert opinion on biological therapy · 2019Review
- An in situ high-throughput screen identifies inhibitors of intracellularProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Demonstration of the broad spectrumAntimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.